|Awarded On||February 21, 2018|
|Title||Tumor Activated Enzyme Inhibitors for the Treatment of Cancer|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas Southwestern Medical Center|
|Principal Investigator/Program Director||Joseph M Ready|
|Cancer Sites||Gallbladder, Liver and Intrahepatic Bile Duct, Lung and Bronchus|
Ideal treatments for cancers kill tumor cells but not normal tissues. Traditional chemotherapies do not meet this ideal because they injure both cancer cells and normal cells. Agents like cisplatin help shrink tumors but cause peripheral pain due to toxicity to nerve tissues. Similarly, many chemotherapies cause nausea because they damage the stomach and intestines. The poor selectivity of traditional therapies not only causes debilitating side effects. It also reduces the effectiveness of drugs because it limits the tolerable dose. In this application, we describe technology that can limit the systemic toxicity of cancer treatments. We discovered that certain cancer types express metaboli...